Press releases, workshop summaries, and editorials

NIH launches partnership to improve success of clinical trials for patients with Parkinson’s disease

“Advancing treatments for Parkinson’s disease is hampered by insufficient understanding of biological networks; drugs aimed at seemingly promising therapeutic targets fail in clinical trials,” said NIH Director Francis S. Collins, M.D., Ph.D. “By combining our expertise and resources, AMP PD partners hope to increase our collective odds of success in accelerating the development of effective treatments for a million Americans who suffer from this debilitating disease.”

NINDS Parkinson's Disease Biomarkers Program Meeting, Bethesda MD (September 22, 2014)

On August 8-9, 2016, representatives from NIH,  Principal Investigators (PIs), advocacy groups, industry, as well as clinical and data management experts from each project sponsored under the National Institute of Neurological Disorders and Stroke (NINDS) Parkinson’s Disease (PD) Biomarkers Program (PDBP) met to discuss progress over the last twelve months in addition to current and future plans for the program. 

NINDS Parkinson's Disease Biomarkers Program Consortium Meeting, Bethesda MD (August 8-9, 2016)

On August 8-9, 2016, representatives from NIH,  Principal Investigators (PIs), advocacy groups, industry, as well as clinical and data management experts from each project sponsored under the National Institute of Neurological Disorders and Stroke (NINDS) Parkinson’s Disease (PD) Biomarkers Program (PDBP) met to discuss progress over the last twelve months in addition to current and future plans for the program.